<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01883128</url>
  </required_header>
  <id_info>
    <org_study_id>1R01CA135089</org_study_id>
    <nct_id>NCT01883128</nct_id>
  </id_info>
  <brief_title>FOcal RECurrent Assessment and Salvage Treatment</brief_title>
  <acronym>FORECAST</acronym>
  <official_title>An Evaluation of a Novel Imaging Based Complex Diagnostic and Therapeutic Pathway Intervention for Men Who Fail Radiotherapy for Prostate Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College London Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College London Hospitals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radiotherapy is the commonest form of prostate cancer treatment in the UK. In one in four&#xD;
      men, radiotherapy will fail to control the cancer. These men are offered hormonal treatment&#xD;
      which has significant side effects. Few men are offered a further treatment such as surgery,&#xD;
      HIFU or cryotherapy. Only half of these men are cancer free at 5 years. The investigators&#xD;
      believe this is due to poor imaging tests such as CT and Bone scan that cannot accurately&#xD;
      detect whether cancer has come back inside or outside of the prostate or both. Also&#xD;
      radiotherapy damages tissue surrounding the prostate which affects tissue healing for example&#xD;
      after surgery. Treating just the cancer in the prostate only (focal treatment) rather than&#xD;
      the whole prostate may limit this damage and cause fewer side-effects. The investigators want&#xD;
      to see if new imaging tests can better identify cancer that has spread outside of the&#xD;
      prostate and areas of cancer inside the prostate. Our new tests are whole-body MRI (for&#xD;
      distant disease) and MRI guided biopsies (MRI-TB) (for local disease). First, the&#xD;
      investigators will compare the results of whole-body MRI to existing imaging tests&#xD;
      (bone-scan, and choline PET/CT) that try to find distant spread. Second, the investigators&#xD;
      will compare the results of MRI-TB to a very detailed and accurate biopsy of the prostate&#xD;
      called template prostate mapping which will show us where and how aggressive the cancer is.&#xD;
      Third, if the cancer is confined to the prostate, the investigators will treat men using&#xD;
      focal salvage therapies HIFU and cryotherapy. The investigators believe that these new&#xD;
      imaging tests could better identify those who will benefit from early hormone treatment and&#xD;
      those who will benefit from local salvage treatment. Our study may help justify carrying out&#xD;
      a larger trial looking at how good the treatment is in controlling cancer in the medium and&#xD;
      long-term.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">April 2014</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Whole-body MRI and Focal salvage therapy</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy of whole body MRI in identifying distant disease</measure>
    <time_frame>2 years</time_frame>
    <description>Whole body MRI lesions suspicious of lymph node, visceral or bone metastases compared to standard care tests&#xD;
- Sensitivity, specificity, negative and positive predictive values of whole-body MRI to detect distant disease compared to standard care tests (isotope bone-scan, PET/CT-scan, with skeletal survey where appropriate) and/or pelvic lymphadenectomy and/or biopsy of distant areas in indeterminate cases</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Can multiparametric MRI accurately detect localised recurrent prostate cancer</measure>
    <time_frame>2 years</time_frame>
    <description>Imaging of Local Disease&#xD;
Transperineal multi-parametric MRI targeted biopsies compared to Template Prostate Mapping biopsies in the detection of UCL definition 2 clinically significant prostate cancer (Gleason &gt;/=3+4 AND/OR Maximum Cancer Core Length &gt;/=4mm in any one biopsy)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To determine urinary incontinence rates after focal salvage therapy to localised recurrent prostate cancer?</measure>
    <time_frame>2 years</time_frame>
    <description>Treatment&#xD;
Continence Presence of urinary incontinence (any pad usage) as determined by the UCLA-EPIC urinary continence questionnaire, at 12 months, in those men with no urinary incontinence at baseline</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">177</enrollment>
  <condition>Progression of Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Whole body MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Comparing the detection rate of metastases of whole body MRI compared to current standard of care tests - Choline PET and Bone scan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRI Targeted Biopsies</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transperineal MRI-targeted biopsies and whole-gland transperineal prostate mapping biopsies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Focal Salvage Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Focal salvage HIFU and cryotherapy of recurrent prostate cancer tumors only</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Whole Body MRI</intervention_name>
    <description>Full parametric MRI using T1W, T2W, Diffusion-weighted and dynamic-contrast-enhanced images at 3Tesla</description>
    <arm_group_label>Whole body MRI</arm_group_label>
    <other_name>Philips Ingenia 3.0T Magnetic Resonance System</other_name>
    <other_name>CE0344</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Focal Salvage Therapy</intervention_name>
    <description>Cryotherapy and HIFU will be used to targeted the areas of tumor only with a margin of normal tissue.</description>
    <arm_group_label>Focal Salvage Therapy</arm_group_label>
    <other_name>HIFU Device name: Sonablate 500</other_name>
    <other_name>HIFU Device Serial Number 1049</other_name>
    <other_name>Cryotherapy Device Name: Seed Net Gold</other_name>
    <other_name>Cryotherapy Serial Number: Cat No FPRCH 2024</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI Targeted biopsies</intervention_name>
    <description>Image registration will be used to target biopsies followed by full mapping biopsies of the prostate. All biopsies will be carried out transperineally</description>
    <arm_group_label>MRI Targeted Biopsies</arm_group_label>
    <other_name>SmartTarget software for image-registration</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Previous external beam radiotherapy with or without neo-adjuvant/adjuvant hormone&#xD;
             therapy&#xD;
&#xD;
          2. Biochemical failure as defined by the Phoenix criteria (PSA nadir + 2ng/ml)&#xD;
&#xD;
          3. Men considering local salvage treatment for radio-recurrent disease&#xD;
&#xD;
          4. Life expectancy of 5 years or more&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have taken any form of hormones (except 5-alpha reductase inhibitors) within the&#xD;
             previous 6 months&#xD;
&#xD;
          2. Unable to have MRI scan as defined by standard care practice&#xD;
&#xD;
          3. Metallic implant likely to cause artefact and reduce scan quality&#xD;
&#xD;
          4. PSA doubling time of 3 months or less&#xD;
&#xD;
          5. PSA value 20ng/ml or greater&#xD;
&#xD;
          6. Prior prostate biopsies following biochemical failure&#xD;
&#xD;
          7. Any prior local intervention to the prostate (e.g., laser/electrical resection or&#xD;
             incision, cryotherapy, HIFU, any other ablative modality, any other radiotherapy, any&#xD;
             other prostate injection therapy for symptoms or cancer control)&#xD;
&#xD;
          8. Unable to have general or regional anaesthesia&#xD;
&#xD;
          9. Unable to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hashim U Ahmed, FRCS, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University College London Hospitals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manit Arya, FRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College London Hospitals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Emberton, FRCS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College London Hospitals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shonit Punwani, FRCR</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College London Hospitals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Abi A Kanthabalan, MBChB</last_name>
    <phone>+44(0)2034479194</phone>
    <email>ana-k@doctors.org.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hashim U Ahmed, FRCS, PhD</last_name>
    <phone>+44(0)2034479194</phone>
    <email>hashim.ahmed@ucl.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hampshire Hospitals NHS Trust</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Hindley, FRCS, MD</last_name>
      <email>Richard.Hindley@hhft.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Richard Hindley, FRCS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abi Kanthabalan</last_name>
      <phone>+44(0)34479194</phone>
      <email>abi-k@doctors.org.uk</email>
    </contact>
    <investigator>
      <last_name>Hashim U Ahmed, FRCS, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>June 18, 2013</study_first_submitted>
  <study_first_submitted_qc>June 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2013</study_first_posted>
  <last_update_submitted>May 8, 2017</last_update_submitted>
  <last_update_submitted_qc>May 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University College London Hospitals</investigator_affiliation>
    <investigator_full_name>Hashim Uddin Ahmed</investigator_full_name>
    <investigator_title>MRC Clinician Scientist and Clinical Lecturer in Urology</investigator_title>
  </responsible_party>
  <keyword>Biochemical Failure</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Radiorecurrent Prostate Cancer</keyword>
  <keyword>MRI Prostate</keyword>
  <keyword>Whole Body MRI</keyword>
  <keyword>Bone Scan</keyword>
  <keyword>Choline PET</keyword>
  <keyword>Focal Salvage Treatment</keyword>
  <keyword>HIFU</keyword>
  <keyword>Cryotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

